Literature DB >> 7927875

Correlation between stromelysin-3 mRNA level and outcome of human breast cancer.

G Engel1, K Heselmeyer, G Auer, M Bäckdahl, E Eriksson, S Linder.   

Abstract

The expression level of stromelysin-3 (ST3) mRNA was analyzed by in situ hybridization of formalin-fixed, paraffin-embedded primary breast-tumor samples from 76 patients. Digital image analysis of the dark-field in situ hybridization signal was used to measure the maximal level of ST3 expression in each tumor. All 55 invasive ductal carcinomas and 9 of 10 invasive lobular carcinomas were positive for ST3. Invasive tumors had significantly higher levels of ST3 than in situ tumors. Furthermore, ST3 levels were higher in invasive ductal carcinomas than in invasive lobular carcinomas. The ST3 expression level was significantly correlated to fatal metastatic disease (mean follow-up 104 months). ST3 levels of < 2,500 units were associated with distant metastasis in 46% of patients, whereas levels of > 2,500 units were associated with metastasis in 79% of patients selected for study. ST3 mRNA levels did not correlate with tumor size, microvessel density, DNA ploidy or estrogen-receptor levels. Studies of ST3 expression may provide information valuable for the understanding of breast cancer biology and for prognosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927875     DOI: 10.1002/ijc.2910580614

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas.

Authors:  I Bolon; M Devouassoux; C Robert; D Moro; C Brambilla; E Brambilla
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations.

Authors:  M M Pacheco; M Mourão; E B Mantovani; I N Nishimoto; M M Brentani
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

3.  Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro.

Authors:  M Balduyck; F Zerimech; V Gouyer; R Lemaire; B Hemon; G Grard; C Thiebaut; V Lemaire; E Dacquembronne; T Duhem; A Lebrun; M J Dejonghe; G Huet
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 4.  Matrix metalloproteinases in remodeling of the normal and neoplastic mammary gland.

Authors:  L A Rudolph-Owen; L M Matrisian
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-04       Impact factor: 2.673

Review 5.  Stromelysin-3 in the biology of the normal and neoplastic mammary gland.

Authors:  M C Rio; O Lefebvre; M Santavicca; A Noël; M P Chenard; P Anglard; J A Byrne; A Okada; C H Régnier; R Masson; J P Bellocq; P Basset
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-04       Impact factor: 2.673

Review 6.  Matrix metalloproteinase inhibitors: applications in oncology.

Authors:  D Yip; A Ahmad; C S Karapetis; C A Hawkins; P G Harper
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

7.  Stromelysin 3 is overexpressed in human pancreatic carcinoma and regulated by retinoic acid in pancreatic carcinoma cell lines.

Authors:  Z von Marschall; E O Riecken; S Rosewicz
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

8.  Stromelysin-3 expression promotes tumor take in nude mice.

Authors:  A C Nöel; O Lefebvre; E Maquoi; L VanHoorde; M P Chenard; M Mareel; J M Foidart; P Basset; M C Rio
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

9.  The role of the tumor microenvironment in regulating angiogenesis.

Authors:  Randolph S Watnick
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

10.  Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response.

Authors:  K J Heppner; L M Matrisian; R A Jensen; W H Rodgers
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.